Piper Jaffray is out with its report today on NuVasive NUVA, raising its PT from $39 to $42.
In a note to clients, Piper Jaffray writes, "We expect that in a stabilizing spine market the stock will continue to outperform relative to management guidance and Street estimates. We reiterate our Overweight rating on NUVA, upping out target from $39 to $42, and view the stock as attractively valued at current levels."
Shares of NUVA closed Monday at $32.36.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in